Literature DB >> 4064358

Direct and maternal aspects of the risk of cataract with partial disorders of galactose metabolism.

A F Winder, A R Fielder, J N Mount, J S Menzies.   

Abstract

Partial deficiencies of the enzymes of galactose metabolism can be associated with cataract, both directly and through maternal effects during pregnancy on enzymatically normal children. However, the associations are modest, variable and not obviously expressing cause and effect. We have recorded ophthalmological and biochemical observations including oral galactose tolerance on families with established enzyme deficiencies and/or cataracts, including possible effects during pregnancy. With the partial disorders a simple relationship between the extent of biochemical abnormality and the risk of cataract is not apparent and the association may be substantially coincidental. Cataract is common, and the attractive possibility that expression is significantly due to heterozygous or lesser deficiency of the enzymes of galactose metabolism, amenable to early dietary control of children or mothers at risk, is on present evidence not well supported.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4064358     DOI: 10.1111/j.1399-0004.1985.tb00387.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  4 in total

Review 1.  Inherited metabolic diseases affecting the carrier.

Authors:  W Endres
Journal:  J Inherit Metab Dis       Date:  1997-03       Impact factor: 4.982

Review 2.  Cataract and metabolic disease.

Authors:  W Endres; Y S Shin
Journal:  J Inherit Metab Dis       Date:  1990       Impact factor: 4.982

3.  Plasma polyol levels in patients with cataract.

Authors:  C Jakobs; A C Douwes; M Brockstedt; F Stellaard; W Endres; Y S Shin
Journal:  J Inherit Metab Dis       Date:  1990       Impact factor: 4.982

4.  Lens sorbitol dehydrogenase deficiency in a patient with congenital cataract.

Authors:  V Vetter; Y S Shin
Journal:  Eur J Pediatr       Date:  1995-05       Impact factor: 3.183

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.